Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Short Interest Report for October

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 109,110 shares, a decrease of 35.4% from the September 30th total of 168,895 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 97,400 shares, the days-to-cover ratio is currently 1.1 days.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on MRKR shares. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a research note on Friday, August 21st. Weiss Ratings raised Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 19th. Finally, Zacks Research upgraded shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Marker Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Marker Therapeutics Stock Performance

NASDAQ:MRKR opened at $0.98 on Monday. Marker Therapeutics has a 12 month low of $0.84 and a 12 month high of $2.46. The firm has a fifty day simple moving average of $1.14 and a 200-day simple moving average of $1.37. The company has a market capitalization of $16.34 million, a P/E ratio of -2.39 and a beta of 1.53.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.16. Equities analysts forecast that Marker Therapeutics will post -0.64 EPS for the current year.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently bought a new stake in Marker Therapeutics stock. Concurrent Investment Advisors LLC bought a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned about 0.41% of Marker Therapeutics as of its most recent SEC filing. 22.39% of the stock is owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors.

The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.